CN111065731B - 血管类器官、产生和使用所述类器官的方法 - Google Patents

血管类器官、产生和使用所述类器官的方法 Download PDF

Info

Publication number
CN111065731B
CN111065731B CN201880040207.8A CN201880040207A CN111065731B CN 111065731 B CN111065731 B CN 111065731B CN 201880040207 A CN201880040207 A CN 201880040207A CN 111065731 B CN111065731 B CN 111065731B
Authority
CN
China
Prior art keywords
vascular
human
cells
collagen
organoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880040207.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111065731A (zh
Inventor
J.佩宁格
R.威默
D.克尔雅施基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imba Molikul Institute Of Biotechnology
Original Assignee
Imba Molikul Institute Of Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imba Molikul Institute Of Biotechnology filed Critical Imba Molikul Institute Of Biotechnology
Publication of CN111065731A publication Critical patent/CN111065731A/zh
Application granted granted Critical
Publication of CN111065731B publication Critical patent/CN111065731B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Prostheses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880040207.8A 2017-06-16 2018-06-15 血管类器官、产生和使用所述类器官的方法 Active CN111065731B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17176335 2017-06-16
EP17176335.2 2017-06-16
PCT/EP2018/065949 WO2018229251A1 (fr) 2017-06-16 2018-06-15 Organoïde de vaisseau sanguin, procédés de production et d'utilisation desdits organoïdes

Publications (2)

Publication Number Publication Date
CN111065731A CN111065731A (zh) 2020-04-24
CN111065731B true CN111065731B (zh) 2024-03-12

Family

ID=59239786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040207.8A Active CN111065731B (zh) 2017-06-16 2018-06-15 血管类器官、产生和使用所述类器官的方法

Country Status (8)

Country Link
US (1) US20200199541A1 (fr)
EP (1) EP3638773A1 (fr)
JP (2) JP2020523027A (fr)
KR (1) KR102656200B1 (fr)
CN (1) CN111065731B (fr)
AU (2) AU2018285579B2 (fr)
CA (1) CA3066959A1 (fr)
WO (1) WO2018229251A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (fr) 2010-05-06 2011-11-10 Children's Hospital Medical Center Procédés et systèmes de conversion de cellules précurseurs en tissus intestinaux par différenciation dirigée
EP3712254A1 (fr) 2014-05-28 2020-09-23 Children's Hospital Medical Center Procédés et systèmes de conversion de cellules précurseurs dans des tissus gastriques à travers la différenciation dirigée
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
EP3609997A4 (fr) 2017-04-14 2021-03-03 Children's Hospital Medical Center Compositions de cellules souches issues de multiples cellules donneuses et leurs procédés de préparation
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (fr) 2017-12-21 2021-09-08 Children's Hospital Medical Center Organoïdes humains numérisés et méthodes d'utilisation de ceux-ci
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
CN111494711B (zh) * 2019-01-31 2023-06-23 华东理工大学 干细胞发生器产生的干细胞用于治疗造血损伤
WO2020160371A1 (fr) 2019-02-01 2020-08-06 The University Of Hong Kong Compositions d'organoïdes innervés et leurs procédés de fabrication
CN113631034B (zh) * 2019-03-29 2024-04-26 公立大学法人横滨市立大学 基质组合物
JPWO2020217409A1 (fr) * 2019-04-25 2020-10-29
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
CA3141814A1 (fr) 2019-05-31 2020-12-03 Children's Hospital Medical Center Compositions organoides faconnees et leurs procedes de fabrication
CA3140249A1 (fr) * 2019-06-24 2020-12-30 Upm-Kymmene Corporation Composition de cellules transplantables comprenant des cellules eucaryotes dans un hydrogel de cellulose nanofibrillaire, son procede de preparation et utilisation de cellulose na nofibrillaire
KR102218303B1 (ko) * 2019-08-26 2021-02-23 연세대학교 산학협력단 혈관 조직을 포함하는 오가노이드의 제조 방법 및 이의 용도
EP3884957A1 (fr) * 2020-03-26 2021-09-29 The University of British Columbia Procédés de traitement de virus et procédés de criblage de réactif anti-virus à l'aide d'organoïdes
CA3182887A1 (fr) * 2020-05-13 2021-11-18 Pfizer Inc. Methodes, therapies et utilisations pour le traitement du cancer
EP4222246A1 (fr) * 2020-09-30 2023-08-09 Corning Incorporated Récipients de culture contenant des substrats de culture cellulaire 3d avec des structures de diffusion
JP7808832B2 (ja) * 2021-04-20 2026-01-30 国立大学法人東京農工大学 ネコ乳腺腫瘍オルガノイド培地用組成物及びネコ乳腺腫瘍オルガノイドの製造方法
WO2023286832A1 (fr) * 2021-07-15 2023-01-19 アステラス製薬株式会社 Cellules de type péricyte exprimant le facteur de croissance endothéliale vasculaire (vegf) à un niveau élevé
WO2023286834A1 (fr) * 2021-07-15 2023-01-19 アステラス製薬株式会社 Cellule de type péricyte exprimant le facteur de croissance endothéliale vasculaire (vegf) à un niveau élevé
US20250145961A1 (en) * 2022-02-15 2025-05-08 The University Of Birmingham Generating bone marrow organoids
CN114540278B (zh) * 2022-03-25 2023-11-21 青岛大学 微血管体外培养方法及培养液
CN116203237B (zh) * 2022-12-05 2026-03-27 中国人民解放军陆军军医大学第一附属医院 一种用于检测周细胞的特异性单重生物标志物ndufa4l2及其应用
CN116376809A (zh) * 2023-04-24 2023-07-04 辽宁博奥晶典启衡颐加生物工程有限公司 一种血管化肠类器官的制备方法及应用
CN116875535B (zh) * 2023-07-19 2024-07-12 首都医科大学附属北京天坛医院 一种烟雾病血管类器官模型及其构建方法
KR20250062598A (ko) * 2023-10-31 2025-05-08 서울대학교산학협력단 내분비 오가노이드 이식용 혈관화 시스템
CN118718096A (zh) * 2024-05-29 2024-10-01 广东省人民医院 一种胰岛细胞外基质支架及其仿生胰岛类器官的制备方法和应用
CN120137886A (zh) * 2025-03-07 2025-06-13 南京医科大学 一种模拟寄生虫感染的血管类器官模型及其应用
CN120519372B (zh) * 2025-07-23 2026-04-03 国科大杭州高等研究院 基于人多能干细胞诱导的静脉血管类器官及其构建方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089426A (zh) * 2008-06-24 2011-06-08 亨利庞加莱南锡第一大学 细胞分化方法及其在血管建立中的应用
CN102165058A (zh) * 2008-07-25 2011-08-24 佐治亚大学研究基金会 中胚层来源的ISL 1+多潜能细胞(IMPs)的组合物、心外膜祖细胞(EPCs)和多潜能CXCR4+CD56+细胞(C56Cs)及其使用方法
CN102858956A (zh) * 2010-02-25 2013-01-02 Abt控股公司 血管生成的调节
CN103620024A (zh) * 2011-06-09 2014-03-05 弗·哈夫曼-拉罗切有限公司 用于使多能干细胞分化为血管床细胞的方法
CN103834613A (zh) * 2012-11-27 2014-06-04 中国科学院上海生命科学研究院 制备多能心血管前体细胞及维持其心血管分化能力的方法
CN104024401A (zh) * 2011-06-10 2014-09-03 荷兰皇家科学院 用于干细胞的培养基
CN104254337A (zh) * 2012-01-27 2014-12-31 桑比欧公司 用于调节血管生成和血管发生的方法和组合物
CN105002143A (zh) * 2015-08-19 2015-10-28 湖南光琇高新生命科技有限公司 一种诱导性多能干细胞定向诱导分化为血管内皮样细胞的方法
CN105209609A (zh) * 2013-03-13 2015-12-30 威斯康星校友研究基金会 用于限定条件下的人多潜能干细胞的血内皮分化的方法和材料
CN105670987A (zh) * 2016-03-21 2016-06-15 杭州市萧山区中医院 一种毛囊干细胞诱导分化为血管内皮细胞的抑制方法
CN105814192A (zh) * 2013-10-09 2016-07-27 加利福尼亚大学董事会 哺乳动物视网膜干细胞产生方法和应用
WO2016174604A1 (fr) * 2015-04-30 2016-11-03 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Moyens et procédés de production de cellules souches de sein

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1365250A (en) 1915-12-20 1921-01-11 Elie W Labombarde Paper receptable for liquids
US4829000A (en) 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1092768A1 (fr) 1999-10-16 2001-04-18 ARTEMIS Pharmaceuticals GmbH Construction pour le piègeage conditionel et la disruption de gènes
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10003521A1 (de) 2000-01-27 2001-08-09 Medigene Ag Vorrichtung zum Herstellen eines dreidimensionalen Matrixkörpers, Multi-Well-Platte, Lösung zum Kultivieren von Säugerkardiomyocyten, Verfahren zum Kultivieren einer Zellkultur, Vorrichtung für die Messung isometrischer Kraftparameter von Zellkulturen sowie Verfahren zum meßbaren Verfolgen von Kontraktionen eines in eine Trägersubstanz eingelagerten Zellgewebes
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US7074611B2 (en) 2001-04-27 2006-07-11 Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2005003317A2 (fr) * 2003-07-01 2005-01-13 Regents Of The University Of Minnesota Vaisseaux sanguins ameliores
EP1662005A1 (fr) 2004-11-26 2006-05-31 FrankGen Biotechnologie AG Vecteurs pièges contenant au moins un enhancer et adéquats pour un "gene trapping" aléatoire ou ciblé
EP1815001B8 (fr) 2004-11-26 2011-03-23 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Cassettes de piege a genes pour l'inactivation genetique conditionnelle aleatoire et ciblee
WO2007140340A2 (fr) 2006-05-25 2007-12-06 Massachusetts Institute Of Technology Formation de réseaux vasculaires à l'aide de cellules souches embryonnaires
US20100124533A1 (en) 2008-11-20 2010-05-20 Medtronic Vascular, Inc. Large Animal Model for Human-Like Advanced Atherosclerotic Plaque
WO2010144678A2 (fr) * 2009-06-10 2010-12-16 The General Hospital Corporation Production de tissu cardiaque humain vascularisé et ses utilisations
WO2011115974A1 (fr) 2010-03-15 2011-09-22 Indiana University Research And Technology Corporation Réseaux vasculaires modifiés comprenant des lumières et matrice de support
CA2867441C (fr) * 2012-03-16 2019-01-15 Novahep Ab Vaisseau sanguin allogeneique forme par genie biologique
EP2743345A1 (fr) 2012-12-13 2014-06-18 IMBA-Institut für Molekulare Biotechnologie GmbH Culture de tissu différencié hétérogène tridimensionnel
WO2014127170A1 (fr) * 2013-02-13 2014-08-21 Wake Forest University Health Sciences Constructions hépatiques biologiquement modifiées et méthodes associées
CA2906188A1 (fr) 2013-03-15 2014-09-18 The Johns Hopkins University Reseau vasculaire auto-organise de cellules souches pluripotentes humaines dans une matrice synthetique
US9506037B2 (en) * 2013-03-15 2016-11-29 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
EP3008169B1 (fr) * 2013-06-10 2021-11-10 Academisch Ziekenhuis Leiden Différentiation et expansion de cellules endothéliales à partir de cellules souches pluripotentes et formation in vitro de structures de type vasculaire
US9868939B2 (en) * 2013-06-12 2018-01-16 Wisconsin Alumni Research Foundation Generating vasculogenic cell populations
WO2015044339A1 (fr) 2013-09-27 2015-04-02 Gomez Maria F Nouveau modèle de rat pour complications vasculaires du diabète
EP3229732B1 (fr) 2014-12-10 2021-04-28 Cormatrix Cardiovascular, Inc. Prothèses vasculaires renforcées
EP3265104A4 (fr) * 2015-03-03 2018-11-07 President and Fellows of Harvard College Procédés de génération de tissu humain fonctionnel
US11332717B2 (en) 2015-07-22 2022-05-17 The Johns Hopkins University Three-dimensional vascular network assembly from induced pluripotent stem cells

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089426A (zh) * 2008-06-24 2011-06-08 亨利庞加莱南锡第一大学 细胞分化方法及其在血管建立中的应用
CN102165058A (zh) * 2008-07-25 2011-08-24 佐治亚大学研究基金会 中胚层来源的ISL 1+多潜能细胞(IMPs)的组合物、心外膜祖细胞(EPCs)和多潜能CXCR4+CD56+细胞(C56Cs)及其使用方法
CN102858956A (zh) * 2010-02-25 2013-01-02 Abt控股公司 血管生成的调节
CN103620024A (zh) * 2011-06-09 2014-03-05 弗·哈夫曼-拉罗切有限公司 用于使多能干细胞分化为血管床细胞的方法
CN104024401A (zh) * 2011-06-10 2014-09-03 荷兰皇家科学院 用于干细胞的培养基
CN104254337A (zh) * 2012-01-27 2014-12-31 桑比欧公司 用于调节血管生成和血管发生的方法和组合物
CN103834613A (zh) * 2012-11-27 2014-06-04 中国科学院上海生命科学研究院 制备多能心血管前体细胞及维持其心血管分化能力的方法
CN105209609A (zh) * 2013-03-13 2015-12-30 威斯康星校友研究基金会 用于限定条件下的人多潜能干细胞的血内皮分化的方法和材料
CN105814192A (zh) * 2013-10-09 2016-07-27 加利福尼亚大学董事会 哺乳动物视网膜干细胞产生方法和应用
WO2016174604A1 (fr) * 2015-04-30 2016-11-03 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Moyens et procédés de production de cellules souches de sein
CN105002143A (zh) * 2015-08-19 2015-10-28 湖南光琇高新生命科技有限公司 一种诱导性多能干细胞定向诱导分化为血管内皮样细胞的方法
CN105670987A (zh) * 2016-03-21 2016-06-15 杭州市萧山区中医院 一种毛囊干细胞诱导分化为血管内皮细胞的抑制方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix;Sravanti Kusuma et al.;PNAS;第110卷(第31期);12601–12606 *
Tissue engineering of blood vessels with endothelial cells differentiated from mouse embryonic stem cells;GAN SHEN et al.;Cell Research;第13卷(第5期);335-341 *

Also Published As

Publication number Publication date
KR20200018779A (ko) 2020-02-20
US20200199541A1 (en) 2020-06-25
AU2018285579B2 (en) 2024-10-24
JP2023126246A (ja) 2023-09-07
JP2020523027A (ja) 2020-08-06
CA3066959A1 (fr) 2018-12-20
WO2018229251A1 (fr) 2018-12-20
CN111065731A (zh) 2020-04-24
AU2025200408A1 (en) 2025-03-27
AU2018285579A1 (en) 2019-12-12
KR102656200B1 (ko) 2024-04-12
EP3638773A1 (fr) 2020-04-22
WO2018229251A9 (fr) 2019-12-19

Similar Documents

Publication Publication Date Title
KR102656200B1 (ko) 혈관 오가노이드, 상기 오가노이드의 제조 및 사용 방법
Wang et al. Functional regeneration and repair of tendons using biomimetic scaffolds loaded with recombinant periostin
JP7854806B2 (ja) 幹細胞／前駆体の固形器官へのパッチ移植
Muller et al. Human adipose stromal-vascular fraction self-organizes to form vascularized adipose tissue in 3D cultures
Dufourcq et al. Secreted frizzled-related protein-1 enhances mesenchymal stem cell function in angiogenesis and contributes to neovessel maturation
US20250145958A1 (en) Generating Vasculogenic Cell Populations
JP6509119B2 (ja) 腎細胞集団及びその使用
WO2006040755A2 (fr) Nouveaux procedes d'identification, d'isolation et de differenciation in vitro de cellules progenitrices vasculogeniques
Choi et al. FGF2-primed 3D spheroids producing IL-8 promote therapeutic angiogenesis in murine hindlimb ischemia
US20140120066A1 (en) Cardiosphere Derived Cell Population and Methods of Use
HUP0900819A2 (en) Lung tissue culture
US12435316B2 (en) Three dimensional human brain tumor models
Yu et al. Enhanced angiogenic potential of adipose-derived stem cell sheets by integration with cell spheroids of the same source
US20200248147A1 (en) Methods of enhancing development of renal organoids and methods of using the same
Snow-Lisy et al. The role of genetically modified mesenchymal stem cells in urinary bladder regeneration
Wang et al. Homozygous MESP1 knock-in reporter hESCs facilitated cardiovascular cell differentiation and myocardial infarction repair
Xiong et al. The Key to Spinal Cord Recovery: Harnessing P21 Inhibition to Boost Neural Stem/Progenitor Cell Proliferation
US20200360563A1 (en) Methods for Vascular Construction and Products Therefrom
KR102050223B1 (ko) 배아줄기세포로부터 소장 오가노이드의 제조방법
Liu An investigation of the novel role of BCL6 signalling in hiPSC-based vascular cell lineage specification
WO2015153586A1 (fr) Traitements utilisant des cellules souches pluripotentes pour les rétinopathies ischémiques
HK40029180B (zh) 血管类器官、产生和使用所述类器官的方法
HK40029180A (en) Blood vessel organoid, methods of producing and using said organoids
US12630796B2 (en) System, device, and method for single-cell encapsulation and culture
Hong et al. Enhanced intramyocardial vascular cell delivery promotes post-myocardial infarction healing by polarizing pro-regenerative neutrophils

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029180

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant